PE20030591A1 - Formulaciones de acitromicina directamente compresibles - Google Patents

Formulaciones de acitromicina directamente compresibles

Info

Publication number
PE20030591A1
PE20030591A1 PE2002001219A PE2002001219A PE20030591A1 PE 20030591 A1 PE20030591 A1 PE 20030591A1 PE 2002001219 A PE2002001219 A PE 2002001219A PE 2002001219 A PE2002001219 A PE 2002001219A PE 20030591 A1 PE20030591 A1 PE 20030591A1
Authority
PE
Peru
Prior art keywords
acitromycin
acithromycin
forms
mixture
solvate
Prior art date
Application number
PE2002001219A
Other languages
English (en)
Inventor
Steven William Collier
Ernest Shing Quan
Brendan Jhon Murphy
Barbara Alice Johnson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030591A1 publication Critical patent/PE20030591A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA MEZCLA GENERALMENTE HOMOGENEA DE DOS O MAS MATERIALES EN FORMA DE PARTICULAS, PARA FORMAR COMPRIMIDOS DE ACITROMICINA POR COMPRESION DIRECTA, QUE COMPRENDE: a)ACITROMICINA NO DIHIDRATADA, NO GRANULADA, SELECCIONADA DE LAS FORMAS: B, D, E, F, ENTRE OTRAS ; Y, b)AL MENOS UN EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE. DONDE, EL ANGULO INTERNO DE FRICCION DE LA MEZCLA ES MENOR DE APROXIMADAMENTE 34°; EL 14%, EN VOLUMEN DEL TOTAL DE PARTICULAS DE ACITROMICINA, TIENE UN DIAMETRO DE 44 µm O MENOS Y LAS FORMAS B Y F PERTENECEN A LA FAMILIA I DE ACITROMICINA Y A UN GRUPO ESPACIAL P21 MONOCLINICO CON DIMENSIONES DE CELDA DE a=16,3+/-0,3 Å, b=16,2+/-0,3 Å, c=18,4+/-0,3 Å Y ß=109+/-2° Y LAS FORMAS D Y E PERTENECEN A LA FAMILIA II DE LA ACITROMICINA AL GRUPO ESPACIAL P212121 ORTORROMBICO, CON DIMENSIONES DE CELDA A a=8,9+/-0,4 Å, b=12,3+/-0,5 Å, c=45,8+/-0,5 Å; SIENDO D UN SOLVATO MONOHIDRATADO DE MONOCICLOHEXANO Y ACITROMICINA Y E UN SOLVATO MONOHIDRATADO DE MONOTETRAHIDROFURANO Y ACITROMICINA. SE REFIERE TAMBIEN A UN PROCESO PARA PREPARAR DICHO COMPRIMIDO, QUE COMPRENDE: 1)FORMACION DE UNA MEZCLA EN SECO DE UNA FORMA A DE ACITROMICINA NO GRANULADA Y (b); Y, 2)COMPRESION DIRECTA DE DICHA MEZCLA EN SECO PARA FORMAR EL COMPRIMIDO
PE2002001219A 2001-12-21 2002-12-13 Formulaciones de acitromicina directamente compresibles PE20030591A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34348001P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
PE20030591A1 true PE20030591A1 (es) 2003-07-12

Family

ID=23346277

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001219A PE20030591A1 (es) 2001-12-21 2002-12-13 Formulaciones de acitromicina directamente compresibles

Country Status (20)

Country Link
US (4) US20030165563A1 (es)
EP (1) EP1455758A1 (es)
JP (1) JP2005513099A (es)
KR (1) KR100632339B1 (es)
CN (1) CN1668282A (es)
AR (1) AR037930A1 (es)
AU (1) AU2002348884A1 (es)
BR (1) BR0215193A (es)
CA (1) CA2469246A1 (es)
IL (1) IL161996A0 (es)
MX (1) MXPA04005105A (es)
NO (1) NO20043110L (es)
NZ (1) NZ532707A (es)
PA (1) PA8562201A1 (es)
PE (1) PE20030591A1 (es)
PL (1) PL371259A1 (es)
RU (1) RU2277914C2 (es)
TW (1) TW200301138A (es)
WO (1) WO2003053416A1 (es)
ZA (1) ZA200403486B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
CA2469246A1 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB0211620D0 (en) * 2002-05-21 2002-07-03 Bioprogress Technology Ltd Powder compaction and enrobing
US20030228370A1 (en) * 2002-06-11 2003-12-11 Michel Serpelloni Orodispersible solid pharmaceutical form
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
EP1648472A2 (en) * 2003-07-01 2006-04-26 Ranbaxy Laboratories, Ltd. Stable oral compositions of azithromycin monohydrate
WO2005004919A2 (en) * 2003-07-02 2005-01-20 Eurand, Inc. Extended release systems for macrolide antibiotics
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
WO2005053651A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
KR20060092281A (ko) * 2003-12-04 2006-08-22 화이자 프로덕츠 인크. 액체 기초 방법에 의한 아지트로마이신 복합입자 투여형
ATE399536T1 (de) 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
WO2006067577A2 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Stable non-dihydrate azithromycin oral suspensions
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
CA2671727C (en) * 2006-12-20 2016-02-16 Genpharm Ulc A composition containing a bisphosphonic acid in combination with vitamin d
CA2694516A1 (en) * 2007-07-31 2009-02-05 Cargill, Incorporated Direct compressible dextrose
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
BRPI0822485A2 (pt) * 2008-03-18 2015-06-16 Aleksander Vladimirovich Dikovskiy Composição farmacêutica para prevenção de disbiose associada com administração enteral de antibióticos.
DK2266581T3 (en) * 2008-03-18 2016-01-11 Dikovskiy Aleksander Vladimirovich PHARMACEUTICAL COMPOSITION OF ANTIBIOTICS AND prebiotics FOR PREVENTION AND TREATMENT OF DYSBIOSE IN ANTIBACTERIAL THERAPY
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
KR20150092385A (ko) 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
US10373279B2 (en) 2014-02-24 2019-08-06 Mindojo Ltd. Dynamic knowledge level adaptation of e-learning datagraph structures
US20160145548A1 (en) * 2014-11-20 2016-05-26 The Procter & Gamble Company Cleaning composition refill for an automatic dishwasher dispensing device
CN105193753A (zh) * 2015-10-30 2015-12-30 成都通德药业有限公司 一种阿奇霉素分散片的制备方法
CN110633487B (zh) * 2019-07-03 2023-03-14 北京中医药大学 直接压片的片剂处方的设计方法
CN111467362B (zh) * 2020-05-09 2021-07-06 北京四环制药有限公司 一种阿奇霉素药用组合物及其制备方法和其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RU2066324C1 (ru) 1987-07-09 1996-09-10 Пфайзер Инк. Кристаллический дигидрат азитромицина и способ его получения
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
EP0758549A4 (en) * 1994-04-26 1997-07-02 Nobuhiro Narita MEDICAL COMPOSITION AS A MEDICINE FOR NON-SMALL CELL CANCER
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
US6068859A (en) * 1994-05-06 2000-05-30 Pfizer Inc. Controlled-release dosage forms of Azithromycin
IL119866A (en) 1996-12-19 1999-12-31 Unipharm Ltd Antibiotic tablet
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
WO1999012552A1 (en) * 1997-09-10 1999-03-18 Merck & Co., Inc. 9a-AZALIDES AS VETERINARY ANTIMICROBIAL AGENTS
US6339063B1 (en) * 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
PL197894B1 (pl) * 1998-11-30 2008-05-30 Teva Pharma Etanolan azytromycyny, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
WO2002009640A2 (en) 2000-08-01 2002-02-07 Shiva Prasad Singh Process for the preparation of anhydrous azithromycin
JP2004530703A (ja) * 2001-05-22 2004-10-07 ファイザー・プロダクツ・インク 結晶形アジスロマイシン
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
PT1446010E (pt) * 2001-10-18 2009-06-08 Teva Pharma Composições de azitromicina estabilizadas
CA2469246A1 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
BR0215175A (pt) * 2001-12-21 2004-12-28 Pfizer Prod Inc Métodos para a granulação úmida de azitromicina
CA2474809A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Dry granulated formulations of azithromycin

Also Published As

Publication number Publication date
IL161996A0 (en) 2005-11-20
US7070811B2 (en) 2006-07-04
MXPA04005105A (es) 2004-08-19
CA2469246A1 (en) 2003-07-03
BR0215193A (pt) 2004-11-16
KR20040066175A (ko) 2004-07-23
US20060024363A1 (en) 2006-02-02
ZA200403486B (en) 2006-05-31
JP2005513099A (ja) 2005-05-12
RU2277914C2 (ru) 2006-06-20
PL371259A1 (en) 2005-06-13
KR100632339B1 (ko) 2006-10-12
AR037930A1 (es) 2004-12-22
WO2003053416A1 (en) 2003-07-03
RU2004118709A (ru) 2005-04-20
NO20043110L (no) 2004-07-20
NZ532707A (en) 2006-07-28
CN1668282A (zh) 2005-09-14
US20050287209A1 (en) 2005-12-29
PA8562201A1 (es) 2003-07-28
US20030165563A1 (en) 2003-09-04
TW200301138A (en) 2003-07-01
US20060024364A1 (en) 2006-02-02
AU2002348884A1 (en) 2003-07-09
EP1455758A1 (en) 2004-09-15

Similar Documents

Publication Publication Date Title
PE20030591A1 (es) Formulaciones de acitromicina directamente compresibles
CO5640076A2 (es) Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento
AR037695A1 (es) Composicion para el tratamiento del cabello
ECSP088106A (es) Formas de dosificación de liberación retardada oral altamente biodisponible del succinato de o-desmetilvenlafaxina
AR029825A1 (es) Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma
ECSP088379A (es) Tabletas dispersables que comprenden deferasirox
ATE493130T1 (de) Opioid enthaltende arzneiform gegen missbrauch
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
AR056575A1 (es) Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo
AR037931A1 (es) Metodo para granulacion humeda de azitromicina
ES2147309T3 (es) Composiciones de ondansetron liofilizadas.
ECSP024397A (es) Combinaciones de inihibidores de dipeptildil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus
AR031547A1 (es) Forma fisica de la sustancia 5-cloro-n-[2-[4-[[[(ciclohexilamino)-carbonil]amino]sulfonil]fenil]etil]-2-metoxibenzamida (gliburida), el uso de dicha sustancia en una tableta o capsula, las tabletas o capsulas que la contienen y las tabletas o capsulas que la contienen asociada con un farmaco para el
ES2181417T3 (es) Formulacion de capsulas o tabletas de efavirenz de disolucion rapida usando super-desintegrantes.
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
CO4940406A1 (es) Composiciones de paracetamol de accion rapida
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
ES2099021B1 (es) Composicion farmaceutica que tiene actividad analgesica.
AR031601A1 (es) Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
AR050574A1 (es) Uso de un compuesto para estimulacion del crecimiento de pelo
AR106180A2 (es) COMPUESTO DE a-AMINOCARBOXIAMIDA QUE ES 5-(4-{[(2-FLUOROFENIL)METIL]OXI}FENIL)PROLINAMIDA
AR062626A1 (es) Comprimidos de polimero de poliestireno sulfonato, su preparacion y uso
AR014881A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprendedicho sensibilizador y dicho agente

Legal Events

Date Code Title Description
FD Application declared void or lapsed